Bellerophon provides business update and reports third quarter 2019 financial results

Bellerophon provides business update and reports third quarter 2019 financial results.q3 loss per share $0.06.q3 earnings per share estimate $-0.07 -- refinitiv ibes data.anticipate initiating pivotal cohort during the first quarter of 2020.bellerophon therapeutics- as of sept 30, co had cash and cash equivalents of $12.8 million, compared to $16.6 million at dec 31, 2018.

BLPH Ratings Summary

BLPH Quant Ranking